Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
TAVIST ALLERGY/SINUS/HEADACHE is an oral tablet combination product marketed by Novartis for symptomatic relief of allergy, sinus, and headache symptoms. The exact active ingredients and mechanism of action are not specified in available data, but the product is positioned as a multi-symptom OTC or near-OTC therapy. It represents a small-molecule formulation approved over two decades ago.
Product is in late-stage lifecycle with approaching loss of exclusivity, suggesting a contracting commercial footprint and potential team downsizing or redeployment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TAVIST presents limited career advancement opportunity due to LOE approaching status and zero linked job openings. This is a sunset product with declining strategic priority, best suited for transition roles or those seeking stable, low-profile portfolio management experience. Career mobility into higher-growth franchises within Novartis should be prioritized.
Worked on TAVIST ALLERGY/SINUS/HEADACHE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.